Navigation Links
Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
Date:7/24/2012

eement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "could," "potential," "may" and similar references to future periods.  Examples of forward-looking statements include our current views as to the potential of NKTR-181 as a new approach to opioid
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 MEDTEC China South 2015 came ... of MEDTEC China 2015, MEDTEC China South has been recognized ... out as a key event for the medical device manufacturing ... years of challenges, this year marks the successful return of the ... after the event first debuted there in 2005. ...
(Date:6/3/2015)...   Health Data Consortium (HDC) , a public-private partnership whose mission ... to improve health and healthcare, today announced Niall Brennan ... Office of Enterprise Data and Analytics at the Centers ... of this year,s Health Data Liberators Award ... ways to help improve the quality and value of ...
(Date:6/3/2015)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that Adapt ... overdose with intranasal naloxone, has commenced a rolling ... the United States Food and Drug Administration (FDA) ... drug intended to treat opioid overdose.  A rolling ...
Breaking Medicine Technology:MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 2CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 3CMS Chief Data Officer and Health Data Advocate Niall Brennan Receives Third Annual Health Data Liberators Award 4Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... 18, 2011 Reportlinker.com announces that a ... its catalogue: China ... http://www.reportlinker.com/p0590608/China-Contract-Research-Organization-CRO-Industry-Report-2010-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc ... high R&D costs of new drugs worldwide, ...
... from Texas has invented a miraculous new medical laser ... inventions and scientific advancements in modern history. The miraculous ... organs to kill harmful germs and bacteria during surgical ... currently contribute to the estimated 100,000 annual deaths attributed ...
Cached Medicine Technology:China Contract Research Organization (CRO) Industry Report, 2010-2011 2China Contract Research Organization (CRO) Industry Report, 2010-2011 3China Contract Research Organization (CRO) Industry Report, 2010-2011 4China Contract Research Organization (CRO) Industry Report, 2010-2011 5New Life Saving Medical Invention Announced by Perry Felix 2
(Date:6/3/2015)... 2015 Johnson & Johnson and its ... to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed ... allegedly used to market the antipsychotic drug. Court ... the Arkansas Attorney General moved to dismiss the case ... Risperdal settlement amounts to just a fraction of the ...
(Date:6/3/2015)... 03, 2015 “ Harmony ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... wants to improve some aspect of their life. , A ... for people with difficulties in their life. However, hypnotherapy is ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... 03, 2015 On the heels of a ... industry by 2020 ( click here to review news ... believe Baltimore has the talent to become a ... genetic code and other biological data are collected and analyzed ... “Baltimore contains all the elements of a perfect storm for ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Dr. Steven ... York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, ... on weekdays to his practice. In most cases, depending on ... of the day they call, they will be seen by ... first priority as a cardiologist is to ensure that people ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... ... Institute to identify regions of the dengue virus and Mycobacterium tuberculosis that can be targeted ... Melbourne, ... (NASDAQ Capital Market: CBTE), is pleased to announce that it has been awarded a major ...
... , NASDAQ: CRME ... Pharma Corp. (NASDAQ: CRME / TSX: COM) today ... its directors, officers and employees (each a "restricted person") to ... pursuant to applicable Canadian and U.S. securities laws, including the ...
... Researchers from Boston University School of Medicine (BUSM) have ... of emphysema. The study, which appears on-line in the ... therapeutic genes in lung tissue for a lifetime after only ... most common inherited form of emphysema seen in young people ...
... less clogged in those who nurse infants, study finds, , ... to breast-feed because of the numerous health benefits it offers ... the health of the mothers, hearts later in life. ... that those who had not breast-fed were much more likely ...
... ... rid of their worst menopause and perimenopause symptoms. Don’t Pause contains other natural supplements ... women experience as they age. , ... (PRWEB) December 21, 2009 -- When a woman starts going through ...
... , NEW YORK, Dec. 21 The Center to Advance ... Diane E. Meier, MD , a pioneer in palliative care, has ... of four 2009-2010 Health and Aging Policy Fellows , Dr. ... process at the Federal level. The HELP committee has jurisdiction over ...
Cached Medicine News:Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 3Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 2Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 3Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 5Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 6Health News:Researchers discover gene therapy to prevent progression of emphysema 2Health News:Breast-Feeding May Protect a Woman's Heart 2Health News:Breast-Feeding May Protect a Woman's Heart 3Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 2Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 3Health News:Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: